NASDAQ:COLL Collegium Pharmaceutical (COLL) Stock Price, News & Analysis $34.07 -0.35 (-1.02%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$34.22 +0.15 (+0.43%) As of 05/22/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Collegium Pharmaceutical Stock (NASDAQ:COLL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get COLL alerts:Sign Up Key Stats Today's Range$33.98▼$35.0150-Day Range$31.99▼$39.3552-Week Range$28.34▼$50.79Volume163,823 shsAverage Volume465,218 shsMarket Capitalization$1.10 billionP/E Ratio16.70Dividend YieldN/APrice Target$57.50Consensus RatingModerate Buy Company Overview Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse. The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S. Food and Drug Administration (FDA) in 2016, and Apadaz® (hydrocodone bitartrate and acetaminophen) tablets. Collegium also markets Rybix® ODT (oxycodone), an orally disintegrating tablet, and has rights to the fentanyl transdermal system ONSOLIS® under a distribution agreement. These products are supported by a dedicated commercial organization and are primarily available in the United States. Headquartered in Wilmington, North Carolina, Collegium maintains research, development and manufacturing operations, including a facility in Richmond, Virginia. Since its incorporation in 2013, the company has expanded its product portfolio and pursued a pipeline of additional abuse-deterrent drug candidates, seeking to address unmet needs in both acute and chronic pain treatment. Collegium is led by a management team with experience in specialty pharmaceuticals and regulatory affairs. Michael Thomas serves as President and Chief Executive Officer, guiding the company’s strategic direction and commercial growth initiatives. Under this leadership, Collegium continues to advance its mission of improving patient safety and outcomes through innovative drug delivery technologies.AI Generated. May Contain Errors. Read More Collegium Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreCOLL MarketRank™: Collegium Pharmaceutical scored higher than 54% of companies evaluated by MarketBeat, and ranked 465th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingCollegium Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialCollegium Pharmaceutical has a consensus price target of $57.50, representing about 68.8% upside from its current price of $34.07.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 3 research reports in the past 90 days.Read more about Collegium Pharmaceutical's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-12.57% Earnings GrowthEarnings for Collegium Pharmaceutical are expected to decrease by -12.57% in the coming year, from $6.76 to $5.91 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is 16.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is 16.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.28.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 3.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Collegium Pharmaceutical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.65% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 14.44, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently decreased by 1.63%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.49 News SentimentCollegium Pharmaceutical has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Collegium Pharmaceutical this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for COLL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,507,572.00 in company stock.Percentage Held by Insiders1.85% of the stock of Collegium Pharmaceutical is held by insiders.Percentage Held by InstitutionsCollegium Pharmaceutical has minimal institutional ownership at this time.Read more about Collegium Pharmaceutical's insider trading history. Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COLL Stock News HeadlinesAnalysts Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PT at $57.50May 21 at 3:49 AM | americanbankingnews.comCollegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst QuestionsMay 18, 2026 | finance.yahoo.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.May 24 at 1:00 AM | Behind the Markets (Ad)Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To KnowMay 17, 2026 | uk.finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (AVAH), Collegium Pharmaceutical (COLL) and Dexcom (DXCM)May 16, 2026 | theglobeandmail.comCollegium Shareholders Back Board, Pay and Auditor ChoicesMay 15, 2026 | tipranks.comCollegium Completes Acquisition of AZSTARYS® from Corium TherapeuticsMay 12, 2026 | globenewswire.comCollegium Pharmaceutical, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comSee More Headlines COLL Stock Analysis - Frequently Asked Questions How have COLL shares performed this year? Collegium Pharmaceutical's stock was trading at $46.30 on January 1st, 2026. Since then, COLL shares have decreased by 26.4% and is now trading at $34.07. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) posted its quarterly earnings data on Thursday, May, 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.24. The business's quarterly revenue was up 8.9% compared to the same quarter last year. Read the conference call transcript. How will Collegium Pharmaceutical's stock buyback program work? Collegium Pharmaceutical's board approved a stock repurchase program on Monday, July 7th 2025, which allows the company to repurchase $150,000,000 in shares, according to EventVestor. This means that the company could purchase up to 15.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's leadership believes its shares are undervalued. When did Collegium Pharmaceutical IPO? Collegium Pharmaceutical (COLL) raised $75 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. Who are Collegium Pharmaceutical's major shareholders? Collegium Pharmaceutical's top institutional investors include Janus Henderson Group PLC (5.63%), Renaissance Technologies LLC (4.53%), Principal Financial Group Inc. (4.00%) and Rubric Capital Management LP (3.95%). Insiders that own company stock include Joseph Ciaffoni, Colleen Tupper, Shirley R Kuhlmann, Gino Santini, David Dieter, Scott Dreyer, Thomas B Smith, Rita J Balice-Gordon, Garen G Bohlin and John Gordon Freund. View institutional ownership trends. How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Collegium Pharmaceutical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Arista Networks (ANET), Netflix (NFLX) and CrowdStrike (CRWD). Company Calendar Last Earnings5/07/2026Today5/24/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 COLL's financial health is in the Red zone, according to TradeSmith. COLL has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COLL CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees210Year Founded2002Price Target and Rating Average Price Target for Collegium Pharmaceutical$57.50 High Price Target$60.00 Low Price Target$56.00 Potential Upside/Downside+68.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$2.04 Trailing P/E Ratio16.70 Forward P/E Ratio5.04 P/E GrowthN/ANet Income$62.87 million Net Margins9.41% Pretax Margin13.59% Return on Equity95.18% Return on Assets16.39% Debt Debt-to-Equity Ratio2.47 Current Ratio1.71 Quick Ratio1.62 Sales & Book Value Annual Sales$780.57 million Price / Sales1.42 Cash Flow$15.21 per share Price / Cash Flow2.24 Book Value$9.63 per share Price / Book3.54Miscellaneous Outstanding Shares32,430,000Free Float31,834,000Market Cap$1.10 billion OptionableOptionable Beta0.76 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:COLL) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
